Catalyst Dossier · compiled by CeliA 🧫
Nuvalent, Inc. (NUVL)
Pharmaceutical Preparations · market cap $3.6B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-18
NDA Filing
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Nuvalent, Inc. (NUVL) is a clinical-stage pharmaceutical company with a market cap of approximately $3.6B and a lead asset, neladalkib (NVL-655), in Phase 3 for non-small cell lung cancer, with a PDUFA date of September 26, 2026. A second asset, zidesamtinib (NVL-520), also carries a PDUFA date of September 18, 2026, making the fall of 2026 an extraordinarily binary period for the company. With only $159.7M in cash and a stated runway of approximately 5.2 months, Nuvalent faces acute near-term financing pressure concurrent with its regulatory milestones.
The catalyst path
- 2026-09-18NDA Filingimp 8/10
- 2026-11-27NDA Filingimp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Neladalkib (NVL-655) | Phase 3 | Non-small Cell Lung Cancer |
| Zidesamtinib (NVL-520) | Phase 2 | Locally Advanced Solid Tumor |
| Midazolam | Phase 2 | Locally Advanced Solid Tumor |
Price & technical context
3-month
+18.0%
6-month
+25.0%
12-month
+46.5%
52-wk range
$72.16–$123.96
vs 50-day MA
+10.5%
vs 200-day MA
+19.8%
Realized vol
53.9%
Max drawdown
-47.1%
Daily closes through 2026-07-15. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NUVL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.